Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease

Epstein, Jenny, Docena, Guillermo, MacDonald, Thomas T., Sanderson, Ian R.·2010·British Journal of Nutrition
DOI 10.1017/s0007114509992510
Open this paper in CoChat — free account

Abstract

Inflammatory bowel disease (IBD) is a major source of morbidity in children and adults. Its incidence is rising, particularly in young people. IBD carries a lifelong risk of cancer, which is proportional to disease duration. Drug and surgical treatments rarely offer cure and often carry a high side effect burden. Dietary therapy is highly effective in Crohn's disease. For these reasons, there is much interest in developing novel dietary treatments in IBD. Curcumin, a component of the spice turmeric, and an anti-inflammatory and anti-cancer agent, shows preclinical and clinical potential in IBD. Its mechanisms of action are unknown. Our aim was to assess the effect of curcumin on key disease mediators p38 mitogen-activated protein kinase (MAPK), IL-1β, IL-10 and matrix metalloproteinase-3 (MMP-3) in the gut of children and adults with IBD. Colonic mucosal biopsies and colonic myofibroblasts (CMF) from children and adults with active IBD were cultured ex vivo with curcumin. p38 MAPK, NF-κB and MMP-3 were measured by immunoblotting. IL-1β and IL-10 were measured by ELISA. We show reduced p38 MAPK activation in curcumin-treated mucosal biopsies, enhanced IL-10 and reduced IL-1β. We demonstrate dose-dependent suppression of MMP-3 in CMF with curcumin. We conclude that curcumin, a naturally occurring food substance with no known human toxicity, holds promise as a novel therapy in IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0007114509992510

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 71

  1. 10.1016/j.coph.2004.06.005 · DOI
  2. de Waal Malefyt, 1993, Direct effects of IL-10 on subsets of human CD4+T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation, J Immunol, 150, 4754, 10.4049/jimmunol.150.11.4754 · DOI
  3. 10.1111/j.1462-5822.2007.00997.x · DOI
  4. 10.1053/j.gastro.2005.09.005 · DOI
  5. 10.1074/jbc.M409024200 · DOI · Paper page
  6. Hoang, 2007, Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2 − / − colonic myofibroblasts, Am J Physiol, 292, G1511
  7. 10.1097/00005176-200007000-00005 · DOI
  8. 10.1111/j.1365-2249.1993.tb05997.x · DOI
  9. 10.1084/jem.190.7.995 · DOI · Paper page
  10. 10.1186/1465-9921-8-71 · DOI
  11. Ridley, 1997, Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels, J Immunol, 158, 3165, 10.4049/jimmunol.158.7.3165 · DOI
  12. 10.1089/107555303321223035 · DOI · Paper page
  13. 10.1016/0092-8674(93)80068-P · DOI
  14. 10.1111/j.1471-4159.2008.05318.x · DOI
  15. Rennick, 2000, Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10( − / − ) mice and intestinal inflammation, Am J Physiol, 278, G829
  16. Binion, 2009, Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin, Am J Physiol, 297, G259
  17. 10.1002/jcp.20549 · DOI
  18. 10.1038/sj.bjp.0702803 · DOI
  19. 10.1016/j.cgh.2006.08.008 · DOI · Paper page
  20. 10.1186/1472-6882-6-10 · DOI
  21. Pender, 2000, Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells, Am J Physiol, 279, G918
  22. Xu, 2003, Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth, Am J Physiol, 285, G20
  23. 10.1136/gut.2008.152496 · DOI
  24. 10.1016/j.gtc.2006.07.008 · DOI
  25. 10.1136/gut.42.3.309 · DOI
  26. 10.1074/jbc.274.1.264 · DOI · Paper page
  27. 10.1111/j.1751-2980.2008.00355.x · DOI
  28. 10.1097/00042737-199905000-00013 · DOI
  29. 10.1097/00005176-200403000-00007 · DOI
  30. Beattie, 1998, Childhood Crohn's disease and the efficacy of enteral diets, Nutrition, 14, 345, 10.1016/S0899-9007(97)00493-0 · DOI
  31. Aggarwal, 2006, Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation, Molecular pharmacology, 69, 195, 10.1124/mol.105.017400 · DOI · Paper page
  32. 10.4049/jimmunol.171.7.3863 · DOI · Paper page
  33. 10.1007/978-0-387-46401-5_9 · DOI
  34. 10.1016/j.bcp.2007.08.016 · DOI
  35. Cho, 2007, Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets, Int J Mol Med, 19, 469
  36. 10.1210/me.2004-0487 · DOI
  37. 10.1097/01.mpg.0000189345.31010.89 · DOI
  38. 10.1007/s10620-005-3032-8 · DOI
  39. 10.1074/jbc.M301580200 · DOI
  40. Yoshida, 1990, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem, 265, 17174, 10.1016/S0021-9258(17)44885-X · DOI
  41. 10.1152/ajplung.2000.279.5.L895 · DOI
  42. 10.4049/jimmunol.168.10.5342 · DOI · Paper page
  43. 10.1007/s10875-006-9066-7 · DOI
  44. 10.1111/j.1745-7254.2006.00322.x · DOI
  45. Jobin, 1999, Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity, J Immunol, 163, 3474, 10.4049/jimmunol.163.6.3474 · DOI
  46. 10.1093/jn/135.8.1859 · DOI
  47. 10.1016/0016-5085(95)90692-4 · DOI · Paper page
  48. 10.1016/0952-7915(92)90082-P · DOI · Paper page
  49. 10.1084/jem.174.4.915 · DOI
  50. Chomarat, 1995, Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10, J Immunol, 154, 1432, 10.4049/jimmunol.154.3.1432 · DOI
  51. 10.1038/39614 · DOI
  52. 10.1097/01.CCM.0000186760.20502.C7 · DOI
  53. 10.1046/j.1365-2036.2001.01093.x · DOI
  54. 10.1111/j.1582-4934.2007.00089.x · DOI
  55. 10.1016/j.cellimm.2008.03.002 · DOI
  56. 10.1189/jlb.0208113 · DOI
  57. 10.4049/jimmunol.165.1.286 · DOI · Paper page
  58. 10.1053/j.gastro.2005.09.032 · DOI
  59. 10.1111/j.1745-7254.2008.00792.x · DOI
  60. 10.1016/j.intimp.2007.08.018 · DOI
  61. 10.1038/sj.onc.1201941 · DOI
  62. 10.1152/ajplung.00311.2006 · DOI
  63. 10.1136/gut.52.11.1587 · DOI · Paper page
  64. 10.1016/j.intimp.2006.11.006 · DOI · Paper page
  65. 10.1111/j.1572-0241.2008.02158.x · DOI
  66. 10.1136/adc.88.11.995 · DOI
  67. 10.1016/S0016-5085(98)70136-2 · DOI
  68. 10.1136/gut.48.4.526 · DOI
  69. 10.1074/jbc.270.42.24995 · DOI
  70. 10.1093/carcin/bgh233 · DOI
  71. 10.1016/S0163-7258(99)00008-X · DOI

Cited by

Metadata

Authors
Epstein, J., Docena, G., MacDonald, T. T., & Sanderson, I. R.
Venue
British Journal of Nutrition
Publisher
Cambridge University Press (CUP)
Published
2009-11-02
Volume
103
Issue
6
Pages
824-832
ISSN
  • 0007-1145
  • 1475-2662
DOI
10.1017/s0007114509992510
Cited by
111
References
3
Language
en
Licence
www.cambridge.org/core/terms (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.